The PD-1 receptor inhibits T-cell activity by interacting with its ligands: PD-L1 on tumor cells and antigen presenting cells, and PD-L2 on tumor cells, activated monocytes and dendritic cells (DC). Here, CD274 is linked to neoplasm.